Keyphrases
Acute Myeloid Leukemia
93%
Pediatric Leukemia
84%
Childhood Acute Lymphoblastic Leukemia
63%
Acute Lymphoblastic Leukemia
55%
Diffuse Intrinsic Pontine Glioma
43%
Pediatric
39%
Dutch
33%
Children with Cancer
29%
Childhood Cancer
29%
Childhood Cancer Survivors
26%
Chemotherapy
25%
Drug Resistance
24%
Relapsed or Refractory Acute Myeloid Leukemia
23%
Kenya
19%
Pediatric Acute Lymphoblastic Leukemia
19%
Overall Survival
19%
Cytarabine
18%
Leukemia Patients
17%
Healthcare Professionals
17%
Event-free Survival
17%
Tumor
16%
Quality of Life
16%
Working Diagnosis
16%
Leukemia
16%
Indonesia
16%
Methotrexate
15%
Childhood Cancer Treatment
15%
Prednisolone
15%
Childhood Cancer Patients
15%
Survivors
14%
Pediatric Oncology
14%
Bortezomib
13%
Ara-C
13%
Pediatric Patients
13%
Treatment Outcome
13%
Oncology
12%
L-asparaginase
12%
Childhood Leukemia
12%
Newly Diagnosed
11%
Healthcare Provider Perspectives
11%
Protease Inhibitors
11%
Cancer Treatment
11%
Netherlands
11%
Randomized Controlled Trial
11%
Health-related Quality of Life
10%
Prognostic Significance
10%
Complete Remission
10%
Doxorubicin
10%
Vincristine-induced Peripheral Neuropathy
10%
Late Effects
10%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Childhood Cancer
74%
Pediatric Acute Myeloid Leukemia
64%
Acute Lymphoblastic Leukemia
62%
Pediatrics
59%
Malignant Neoplasm
40%
Chemotherapy
39%
Pontine Glioma
27%
Overall Survival
25%
Disease
23%
Neoplasm
19%
Event Free Survival
19%
Cancer Therapy
18%
Leukemia
18%
Acute Myelogenous Leukemia
18%
In Vitro
18%
Drug Resistance
13%
Quality of Life
13%
Health Care Provider
12%
Acute Leukemia
12%
Cytarabine
12%
Radiation Therapy
12%
Adolescence
12%
Vincristine
11%
Leukemia Cell
11%
Pediatrics Patient
11%
Clinical Trial
11%
Survival Rate
11%
Proteasome Inhibitor
10%
Systematic Review
10%
Ganglioneuroblastoma
10%
Diagnosis
9%
Bortezomib
9%
Retrospective Study
9%
Liposomal Daunorubicin
9%
Minimal Residual Disease
9%
Prognostic Factor
9%
Randomized Controlled Trial
8%
Oncology
8%
Proteasome
8%
Complementary and Alternative Medicine
8%
Cancer
8%
Supportive Care
8%
Childhood Leukemia
7%
Wilms' Tumor
7%
High Risk Population
7%
Ganglioglioma
7%
Low and Middle Income Countries
7%
Glomerular Filtration Rate
6%
Hazard Ratio
6%